Last updated 16 days ago
A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101)
250 patients around the world
Available in Spain, Chile, Argentina, United States
The study duration per participant is approximately 24 months (inclusive of follow-up).
Cohorts A, B, C, and D have been completed.
Synthorx, Inc, a Sanofi company
2Research sites
250Patients around the world
This study is for people with
Advanced tumors
Solid tumors
Requirements for the patient
From 18 Years
All Gender
Medical requirements
StudyHAMMER
SponsorSynthorx, Inc, a Sanofi company
Conditions
Solid tumors
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT04009681
